Medicure Inc (MPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicure Inc (MPH) has a cash flow conversion efficiency ratio of 0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$386.00K ≈ $279.23K USD) by net assets (CA$11.57 Million ≈ $8.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medicure Inc stock valuation for the company's overall valuation and market capitalisation.
Medicure Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Medicure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medicure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicure Inc ranked by their cash flow conversion efficiency. Explore Medicure Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CodeMill AB
ST:CDMIL
|
0.052x |
|
DEER HORN METS
F:G1J
|
0.044x |
|
Fabrity Holding S.A.
WAR:FAB
|
0.028x |
|
Alticast Corporation
KQ:085810
|
-0.062x |
|
TMK Energy Ltd
AU:TMK
|
-0.030x |
|
Substrate AI S.A.
MC:SAI
|
0.010x |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
N/A |
|
Alarko Gayrimenkul Yatirim Ortakligi AS
IS:ALGYO
|
0.067x |
Annual Cash Flow Conversion Efficiency for Medicure Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Medicure Inc from 2000 to 2025. View MPH live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$12.91 Million ≈ $9.34 Million |
CA$-560.00K ≈ $-405.10K |
-0.043x | -165.46% |
| 2024-12-31 | CA$20.78 Million ≈ $15.03 Million |
CA$1.38 Million ≈ $996.10K |
0.066x | -36.58% |
| 2023-12-31 | CA$19.90 Million ≈ $14.39 Million |
CA$2.08 Million ≈ $1.50 Million |
0.104x | +20.07% |
| 2022-12-31 | CA$21.00 Million ≈ $15.19 Million |
CA$1.83 Million ≈ $1.32 Million |
0.087x | -59.83% |
| 2021-12-31 | CA$18.41 Million ≈ $13.32 Million |
CA$3.99 Million ≈ $2.89 Million |
0.217x | +285.19% |
| 2020-12-31 | CA$19.15 Million ≈ $13.85 Million |
CA$-2.24 Million ≈ $-1.62 Million |
-0.117x | +78.47% |
| 2019-12-31 | CA$26.94 Million ≈ $19.49 Million |
CA$-14.64 Million ≈ $-10.59 Million |
-0.543x | -6219.98% |
| 2018-12-31 | CA$83.59 Million ≈ $60.47 Million |
CA$742.27K ≈ $536.95K |
0.009x | -96.73% |
| 2017-12-31 | CA$80.71 Million ≈ $58.38 Million |
CA$21.92 Million ≈ $15.86 Million |
0.272x | +65.07% |
| 2016-12-31 | CA$38.96 Million ≈ $28.18 Million |
CA$6.41 Million ≈ $4.64 Million |
0.165x | +414.14% |
| 2015-12-31 | CA$4.46 Million ≈ $3.23 Million |
CA$142.79K ≈ $103.30K |
0.032x | +126.41% |
| 2014-12-31 | CA$-3.91 Million ≈ $-2.83 Million |
CA$473.97K ≈ $342.86K |
-0.121x | -542.33% |
| 2013-12-31 | CA$-5.88 Million ≈ $-4.25 Million |
CA$110.88K ≈ $80.21K |
-0.019x | -108.24% |
| 2012-12-31 | CA$-4.33 Million ≈ $-3.13 Million |
CA$-990.48K ≈ $-716.50K |
0.229x | +199.88% |
| 2011-12-31 | CA$-1.82 Million ≈ $-1.32 Million |
CA$417.29K ≈ $301.86K |
-0.229x | -1190.93% |
| 2010-12-31 | CA$-26.89 Million ≈ $-19.45 Million |
CA$477.48K ≈ $345.40K |
-0.018x | -130.50% |
| 2009-12-31 | CA$-24.96 Million ≈ $-18.05 Million |
CA$-1.45 Million ≈ $-1.05 Million |
0.058x | -89.08% |
| 2008-12-31 | CA$-19.55 Million ≈ $-14.14 Million |
CA$-10.42 Million ≈ $-7.54 Million |
0.533x | -91.65% |
| 2007-12-31 | CA$-6.56 Million ≈ $-4.74 Million |
CA$-41.86 Million ≈ $-30.28 Million |
6.386x | +967.70% |
| 2006-12-31 | CA$34.31 Million ≈ $24.82 Million |
CA$-25.25 Million ≈ $-18.26 Million |
-0.736x | -115.75% |
| 2005-12-31 | CA$37.17 Million ≈ $26.89 Million |
CA$-12.68 Million ≈ $-9.17 Million |
-0.341x | +79.25% |
| 2004-12-31 | CA$7.34 Million ≈ $5.31 Million |
CA$-12.07 Million ≈ $-8.73 Million |
-1.644x | -476.36% |
| 2003-12-31 | CA$21.57 Million ≈ $15.60 Million |
CA$-6.15 Million ≈ $-4.45 Million |
-0.285x | +64.61% |
| 2002-12-31 | CA$4.94 Million ≈ $3.58 Million |
CA$-3.98 Million ≈ $-2.88 Million |
-0.806x | -73.80% |
| 2001-12-31 | CA$8.99 Million ≈ $6.50 Million |
CA$-4.17 Million ≈ $-3.01 Million |
-0.464x | +34.57% |
| 2000-12-31 | CA$3.85 Million ≈ $2.79 Million |
CA$-2.73 Million ≈ $-1.97 Million |
-0.709x | -- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more